Phosphorylation of TOPK at Y74, Y272 by Src increases the stability of TOPK and promotes tumorigenesis of colon

T-LAK cell-originated protein kinase (TOPK), a serine/threonine protein kinase, is highly expressed in a variety of tumors and associated with a poor prognosis of human malignancies. However, the activation mechanism of TOPK is still unrevealed. Herein, first we found that Src directly bound with and phosphorylated TOPK at Y74 and Y272 in vitro. Anti-phospho-TOPK at Y74 was prepared, the endogenous phosphorylation of TOPK at Y74 was detected in colon cancer cells, and the phosphorylation was inhibited in cells expressing low levels of Src. Subsequently, we stably transfected Y74 and Y272 double mutated TOPK (TOPK-FF) into JB6 or SW480 cells, and observed that both the anchorage-independent growth ability and tumorigenesis of TOPK-FF cells were suppressed compared with those of wild type TOPK (TOPK-WT) ex vivo and in vivo. The phosphorylation level of TOPK substrate, Histone H3 at Ser10 also decreased dramatically ex vivo or in vivo. Moreover, we showed that Src could inhibit the ubiquitination of TOPK. Transiently expressed TOPK-WT was more stable than TOPK-FF in pause and chase experiment. Endogenous TOPK was more stable in Src wild type (Src+/+) MEFs than in Src knockout (Src−/−). Taken together, our results indicate that Src is a novel upstream kinase of TOPK. The phosphorylation of TOPK at Y74 and Y272 by Src increases the stability and activity of TOPK, and promotes the tumorigenesis of colon cancer. It may provide opportunities for TOPK based prognosis and targeted therapy for colon cancer patients.

[1]  Y. Li,et al.  TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun , 2016, Oncotarget.

[2]  J. Bergh,et al.  The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer , 2015, Journal of internal medicine.

[3]  P. Chiao,et al.  ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer , 2015, Cell Research.

[4]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[5]  Yusuke Nakamura,et al.  TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis , 2014, Science Translational Medicine.

[6]  G. Binefa,et al.  Colorectal cancer: from prevention to personalized medicine. , 2014, World journal of gastroenterology.

[7]  S. Rath,et al.  Expression of PDZ-binding kinase/T-LAK cell-originated protein kinase (PBK/TOPK) in human urinary bladder transitional cell carcinoma. , 2014, Immunobiology.

[8]  A. Elfiky,et al.  The role of Src in colon cancer and its therapeutic implications. , 2014, Clinical colorectal cancer.

[9]  S. Maddika,et al.  TOPK and PTEN participate in CHFR mediated mitotic checkpoint☆ , 2013, Cellular signalling.

[10]  Hong-Bin Fang,et al.  c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas. , 2013, Leukemia research.

[11]  M. Duffy,et al.  Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer , 2013, BMC Cancer.

[12]  Yong-Yeon Cho,et al.  Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth. , 2012, Cancer research.

[13]  J. Raufman,et al.  Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[14]  Ji-shuai Zhang,et al.  Rack1 protects N-terminal phosphorylated c-Jun from Fbw7-mediated degradation , 2012, Oncogene.

[15]  T. Chou,et al.  Overexpression of T‐LAK cell‐originated protein kinase predicts poor prognosis in patients with stage I lung adenocarcinoma , 2012, Cancer science.

[16]  A. Bode,et al.  Coffee phenolic phytochemicals suppress colon cancer metastasis by targeting MEK and TOPK. , 2011, Carcinogenesis.

[17]  Zhenqiu Liu,et al.  PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21 , 2010, Oncogene.

[18]  Christopher Logothetis,et al.  Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. , 2010, Cancer treatment reviews.

[19]  Yusuke Nakamura,et al.  Critical roles of LGN/GPSM2 phosphorylation by PBK/TOPK in cell division of breast cancer cells , 2010, Genes, chromosomes & cancer.

[20]  Ji-shuai Zhang,et al.  T-LAK Cell-originated Protein Kinase (TOPK) Phosphorylation of Prx1 at Ser-32 Prevents UVB-induced Apoptosis in RPMI7951 Melanoma Cells through the Regulation of Prx1 Peroxidase Activity* , 2010, The Journal of Biological Chemistry.

[21]  Filip Lardon,et al.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. , 2010, The oncologist.

[22]  S. Kopetz,et al.  The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy. , 2010, Clinical colorectal cancer.

[23]  U. Rix,et al.  Dasatinib in solid tumors , 2010, Expert opinion on investigational drugs.

[24]  Yusuke Nakamura,et al.  Critical roles of T‐LAK cell‐originated protein kinase in cytokinesis , 2010, Cancer science.

[25]  L. Mazzucchelli,et al.  Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients , 2009, British Journal of Cancer.

[26]  Y. Abe,et al.  A mitotic kinase TOPK enhances Cdk1/cyclin B1-dependent phosphorylation of PRC1 and promotes cytokinesis. , 2007, Journal of molecular biology.

[27]  Weiya Ma,et al.  Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. , 2007, Gastroenterology.

[28]  Feng Zhu,et al.  T-lymphokine-activated killer cell-originated protein kinase functions as a positive regulator of c-Jun-NH2-kinase 1 signaling and H-Ras-induced cell transformation. , 2007, Cancer research.

[29]  R. O'Connor,et al.  PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response , 2007, Oncogene.

[30]  A. Bode,et al.  Lymphokine-Activated Killer T-Cell-Originated Protein Kinase Phosphorylation of Histone H2AX Prevents Arsenite-Induced Apoptosis in RPMI7951 Melanoma Cells , 2006, Clinical Cancer Research.

[31]  Yusuke Nakamura,et al.  PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. , 2006, Cancer research.

[32]  A. Rapoport,et al.  Expression of PDZ-binding kinase (PBK) is regulated by cell cycle-specific transcription factors E2F and CREB/ATF. , 2006, Leukemia research.

[33]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[34]  Yong-Yeon Cho,et al.  Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation. , 2005, Cancer research.

[35]  Y. Abe,et al.  Characterization of a MAPKK-like protein kinase TOPK. , 2004, Biochemical and biophysical research communications.

[36]  Nikolaj Blom,et al.  Phospho.ELM: A database of experimentally verified phosphorylation sites in eukaryotic proteins , 2004, BMC Bioinformatics.

[37]  Heike Allgayer,et al.  Activation of Src kinase in primary colorectal carcinoma , 2002, Cancer.

[38]  J. Toretsky,et al.  PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells. , 2001, Blood cells, molecules & diseases.

[39]  Martin Gs.  The hunting of the Src. , 2001 .

[40]  G. Martin.  The hunting of the Src , 2001, Nature Reviews Molecular Cell Biology.

[41]  C. Allis,et al.  Signaling to Chromatin through Histone Modifications , 2000, Cell.

[42]  Y. Abe,et al.  Cloning and Expression of a Novel MAPKK-like Protein Kinase, Lymphokine-activated Killer T-cell-originated Protein Kinase, Specifically Expressed in the Testis and Activated Lymphoid Cells* , 2000, The Journal of Biological Chemistry.

[43]  D. Branton,et al.  Characterization of PDZ-binding kinase, a mitotic kinase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  G. Martin,et al.  Transformation by v-Src: Ras-MAPK and PI3K-mTOR mediate parallel pathways. , 1999, Molecular biology of the cell.

[45]  S. Curley,et al.  Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. , 1993, The Journal of clinical investigation.

[46]  J. Pipas,et al.  pp60c-src activation in human colon carcinoma. , 1989, The Journal of clinical investigation.

[47]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.